



# *The art of partnerships*

**Developing Countries Vaccine Manufacturers Network**

**Speakers' Book**

**19th Annual General Meeting**


**29<sup>th</sup> October – 1<sup>st</sup> November 2018, Kunming, China.**

<p><b>Day 1, 29<sup>th</sup> October 2018</b>      10:00 - 12:30</p> <p>Satellite Workshop for DCVMN corporate members only: Responsible Innovation and the Future Vaccine Manufacturing Hub - Hosted by The Future Vaccine Hub</p>		
<p><b>Chair: Mr. Robin Shattock</b></p> 	<p>Head of Mucosal Infection and Immunity, Department of Medicine, Imperial College London</p>	<p>Robin Shattock's research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. He oversees a portfolio of research that is supported by 26 members of staff and has published over 160 peer reviewed articles in this area.</p>
<p><b>Co-chair: Mr. Karma Kothari</b></p> 	<p>Responsible for the Future Vaccine Manufacturing Research hub (FVMR)</p>	<p>Karma Kothari focuses on coordinating/accelerating the development of at least 4 vaccine platforms. Prior, he headed cGMP operations of Medical Diagnostics in USA, Japan and UK. He obtained his Bachelor of Science from King's College and PhD from the University of London. He later obtained a Master's in Technology Management from the University of Washington.</p>
<p><b>Mr. Xiao-Ning Xu</b></p> 	<p>Professor, Chair in Human Immunology, Imperial College London</p>	<p>Xiao-Ning Xu has served as Medical Research Council (MRC) Senior Clinical Scientist, project leader, and tenured programme leader at MRC Human Immunology Unit, Oxford University. In 2010, he joined Novartis as the Head of Novartis Vaccines Research China and in 2013 he became the Chair professor in Human Immunology at the Imperial College London.</p>

<p><b>Mr. Imre Berger</b></p> 	<p>Director of the BBSRC/EPSRC research centre for synthetic biology, BrisSynBio, University of Bristol</p>	<p>Imre Berger was trained as a biochemist and molecular biologist. In 2007, he became Group Leader and Principal Investigator at the European Molecular Biology Laboratory. In 2014, he was appointed Full Professor at the School of Biochemistry, University of Bristol. Since 2017, he is Director of the BBSRC/EPSRC research centre for synthetic biology at BrisSynBio.</p>
<p><b>Mr. Rongjun Chen</b></p> 	<p>Senior Lecturer, Department of Chemical Engineering, Imperial College London</p>	<p>Rongjun Chen started his independent academic career as Group Leader and BHRC Senior Translational Research Fellow at the University of Leeds in 2009. He moved to Imperial London as Lecturer in 2013 and was promoted to Senior Lecturer in 2016. He holds a PhD on polymer drug delivery from the University of Cambridge.</p>
<p><b>Mr. Park Page</b></p> 	<p>Principal Scientist, Division of Virology, NIBSC</p>	<p>After his PhD in Comparative Immunology, Mark Page went to St George's Hospital Medical School as a post-doctoral research fellow and then moved to University College London. He then took up a position at NIBSC, the pharmaceutical industry and then back to NIBSC with a focus on viral vaccines research and development. He also holds a BSc in Zoology.</p>
<p><b>Mr. Zoltan Kis</b></p> 	<p>Research Associate, Centre for Process Systems Engineering, Imperial College</p>	<p>Zoltán Kis is a Research Associate at the Centre for Process Systems Engineering in the Future Vaccine Manufacturing Hub. Prior, Zoltán was a Research Associate at the Institute for Integrated Economic Research (IIER) think-tank and a Visiting Academic at the Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London.</p>

<p><b>Mr. Ted Fjällman</b></p> 	<p>Chief Executive Officer, Prokarium Ltd</p>	<p>Prior to joining Prokarium-a biotech company focused on global health and innovation, Ted held a clinical research position at Sahlgrenska Hospital and has worked as a strategy consultant. Mr. Fjällman is a member of the international Bacterial Vaccines Network management board, and an active member in the UK BioIndustry Association.</p>
<p><b>Day 1, 29<sup>th</sup> October 2018</b></p>	<p>14:00 - 16:00</p>	<p>Satellite Symposium on Responsible Innovation: Cost-effective manufacturing and economies of scale</p>
<p><b>Chair: Mr. Chin Bin Tan</b></p> 	<p>Head of Technology Management, Asia Pacific, Merck</p>	<p>Chin Bin Tan is the head of the commercial function of Technical Field Marketing as well as Marketing Communications in Asia Pacific for Merck LifeScience, Process Solutions. He previously worked as Director, Head of Sales, Process solutions for Merck Millipore. He holds a degree in Chemical Engineering from the National University of Singapore.</p>
<p><b>Co-Chair: Mr. Ted Prusik</b></p> 	<p>Co-founder and Senior Vice President, Temptime</p>	<p>Ted's inventions helped create Temptime's technology that monitors the temperature of vaccines and other biologics to support global health organizations with preventing the administration of vaccines that have been compromised by high levels of heat or cold. He received his bachelor's degree in chemistry from Bucknell University and his master's and PhD degrees in chemical physics from New York University.</p>
<p><b>Mr. Ranjeet Patil</b></p> 	<p>Market segment strategy and portfolio management, Merck</p>	<p>Ranjeet Patil heads a global team focused on development and execution of marketing strategy vaccine and viral therapies market. He holds a Bachelor in Biotechnology Engineering and a Master of Science in Biotechnology and Chemical Engineering Mathematics.</p>

<p><b>Mr. Mats Lundgren</b></p> 	<p>Director, GE Healthcare Life Sciences</p>	<p>Mats Lundgren has more than 25 years of experience in vaccinology; as Customer Applications Director at GE, Mats helps companies to implement modern processes with the goal of achieving more efficient production and higher vaccine quality. He holds a PhD in Immunology, Cell, and Molecular Biology and a post-doctoral training.</p>
<p><b>Mr. Tim Kram</b></p> 	<p>General Manager, Rommelag Engineering US office</p>	<p>Tim Kram is an Engineer and pharmaceutical business development professional. For the past 15 years, Tim Kram has worked with companies to develop aseptic product fill/finish solutions using Blow/Fill/Seal technology. He received a B.S. in Electrical Engineering from the Missouri University of Science and Technology.</p>
<p><b>DAY 2, 30<sup>th</sup> October 2018</b></p>		
<p><b>Day 2, 30<sup>th</sup> October 2018</b></p>		
<p>9:00 - 10:00 Plenary Opening Session</p>		
<p><b>Chair:</b> <b>Ms. Mahima Datla</b></p> 	<p>Managing Director, Biological E</p>	<p>Mahima Datla oversees strategic operations and leads the work related to public policy at BE. Mahima is the President of DCVMN's Executive Committee and is currently a member of FICCI and CII National Biotech committees. She is a GHIT fund board member and also an alternate board member with GAVI.</p>
<p><b>Co-Chair: Mr. Li Qihan</b></p> 	<p>Director, Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS)</p>	<p>Mr. Qihan has obtained his B. Sc. from Kunming Medical College then his Ph.D. from Peking Union Medical College and undergone Post-doctor training in MIT. His current research focus is virus vaccines, which mainly include poliovirus attenuated and inactivated vaccine; attenuated and hepatitis inactivated A vaccine; EV71 inactivated vaccine and CA16 inactivated vaccine; Mumps attenuated vaccine.</p>

<p><b>Opening address: Ms. Mahima Datla</b></p> 	<p>Managing Director, Biological E</p>	<p>Mahima Datla oversees strategic operations and leads the work related to public policy at BE. Mahima is the President of DCVMN's Executive Committee and is currently a member of FICCI and CII National Biotech committees. She is a GHIT fund board member and also an alternate board member with GAVI.</p>
<p><b>Co-Chair: Mr. Li Qihan</b></p> 	<p>Director, Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS)</p>	<p>Mr. Qihan has obtained his B. Sc. from Kunming Medical College then his Ph.D. from Peking Union Medical College and undergone Post-doctor training in MIT. His current research focus is virus vaccines, which mainly include poliovirus attenuated and inactivated vaccine; attenuated and hepatitis inactivated A vaccine; EV71 inactivated vaccine and CA16 inactivated vaccine; Mumps attenuated vaccine.</p>
<p><b>Inaugural Address: Ministry of Health and Welfare China/Yunnan</b></p>		
<p><b>Inaugural Speech: Mrs. Mariangela Simao</b></p> 	<p>Assistant Director- General for Drug Access, Vaccines and Pharmaceuticals, World Health Organization (WHO)</p>	<p>Mrs. Simao was Director of Community Support, Social Justice and Inclusion at UNAIDS. She has also experience working in the Brazilian public health system and has played an active role in enhancing access and decentralizing health services in the country. She was trained as a pediatrician in Brazil and holds an MSc degree in public health from University of London.</p>

<b>Day 2, 30<sup>th</sup> October 2018</b>	10:30 - 11:30	Partnerships for Vaccines' Forum
<b>Chair:</b> <b>Mrs. Lingjiang Yang</b> 	Manager of International Business and Cooperation, Chengdu Institute of Biological Products Co., Ltd. (CDIBP)	Ms. Lingjiang Yang is Manager of International Business and Cooperation of CDIBP. Lingjiang is responsible for all international cooperation development and management, as well as taking care of the international marketing. Her experience as the project coordinator of the WHO prequalification project of live Japanese encephalitis vaccine has given her insights of global vaccine industry.
<b>Co-chair: Mr. Hun Kim</b> 	Head Vaccines Research & BD, SK bioscience Co., Ltd	Hun Kim is head of Vaccine Research & Business Development at SK bioscience Co., Ltd. Mr. Kim's role at the company is to oversee its vaccine portfolios from both the business and R&D perspective. Under his oversight as Head of R&D, the company successfully developed and received approval for cell-culture based influenza vaccine products, SKYCellflu.
<b>Mr. Andrin Oswald</b> 	Director, Life Sciences Partnerships, BMGF	Mr. Andrin Oswald is the director of Life Sciences Partnerships at the foundation, overseeing the foundation's engagements with corporations. Before joining the foundation in 2016, he was the CEO and Division Head of Novartis Vaccines and Diagnostics from 2008 to 2015. He obtained his medical degree from University of Geneva.
<b>Mr. Steve Davis</b> 	President & CEO, PATH	Steve is PATH's president and CEO since 2012. Prior, he was director of Social Innovation at McKinsey & Company, CEO of the media firm Corbis, and interim director of the Infectious Disease Research Institute. Steve earned his BA from Princeton University, his MA in Chinese studies from the University of Washington, and his law degree from Columbia University.

<p><b>Ms. Etleva Kadilli</b></p> 	<p>Director, UNICEF's Supply Division</p>	<p>Etleva Kadilli is responsible for the provision of supplies through direct UNICEF programmes, cooperation with Governments and partners. Prior, Ms. Kadilli was Deputy Director in charge of the management of UNICEF's supply response to humanitarian crises, contracting policy and procedures, quality assurance of UNICEF-procured products, global logistics operations and the professional development of UNICEF's supply and logistics staff.</p>
<p><b>Day 2, 30<sup>th</sup> October 2018</b>      11:30 - 12:30      Vaccine innovation through partnerships Panel Discussion</p>		
<p><b>Moderator:</b> <b>Mr. Joshua Chu</b></p> 	<p>Executive Vice President of Vaccines and Cancer, the Clinton Health Access Initiative (CHAI)</p>	<p>Joshua is responsible for CHAI's work to accelerate the introduction of new vaccines and increase the affordability of vaccines and cold chain equipment. He oversees CHAI's work in cancer and will be leading new programs in diabetes and cardiovascular diseases. He obtained his BSc from the University of Pennsylvania. He later obtained a Mphil in Development Studies from University of Cambridge.</p>
<p><b>Mr. Steve Davis</b></p> 	<p>President &amp; CEO, PATH</p>	<p>Steve is PATH's president and CEO since 2012. Prior, he was director of Social Innovation at McKinsey &amp; Company, CEO of the media firm Corbis, and interim director of the Infectious Disease Research Institute. Steve earned his BA from Princeton University, his MA in Chinese studies from the University of Washington, and his law degree from Columbia University.</p>
<p><b>Mr. Andrin Oswald</b></p> 	<p>Director, Life Sciences Partnerships, BMGF</p>	<p>Mr. Andrin Oswald is the director of Life Sciences Partnerships at the foundation, overseeing the foundation's engagements with corporations. Before joining the foundation in 2016, he was the CEO and Division Head of Novartis Vaccines and Diagnostics from 2008 to 2015. He obtained his medical degree from University of Geneva.</p>

<p><b>Mrs. Mariangela Simao</b></p> 	<p>Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals, World Health Organization (WHO)</p>	<p>Mrs. Simao was Director of Community Support, Social Justice and Inclusion at UNAIDS. She has also experience working in the Brazilian public health system and has played an active role in enhancing access and decentralizing health services in the country. She was trained as a pediatrician in Brazil and holds an MSc degree in public health from University of London.</p>
<p><b>Mr. Maurício Zuma Medeiros</b></p> 	<p>General Director, BioManguinhos (the Institute of Technology on Immuno biologicals of Fiocruz)</p>	<p>Mr. Zuma has been a manager for 30 years in various areas of management, focused on results and a permanent search for management solutions for the advancement of public management. He is D.Phil. in Technology and Innovation Management by SPRU/University of Sussex – UK.</p>
<p><b>Mr. Patrick Tippoo</b></p> 	<p>Head of Science &amp; Innovation, The Biovac Institute</p>	<p>Patrick Tippoo heads the Product Development and Business Development at The Biovac Institute. He has been with Biovac since its inception in 2003. Patrick's responsibilities include strategic alliances and local &amp; international partnering opportunities with respect to product development and inbound and outbound technology transfer projects.</p>

Day 2, 30 <sup>th</sup> October 2018		14:00 - 15:00	Vaccines R&D Panel Discussion
<p><b>Moderator:</b> <b>Mr. Viliam Pavliak</b></p> 	<p>Head of Vaccine Development Science Unit, International Vaccine Institute (IVI)</p>	<p>Mr. Pavliak obtained his PhD in Biochemistry from the Slovak Technical University. Prior joining IVI, he was Director at Pfizer Vaccine Research and Development, and at Wyeth Research in USA. He previously led preclinical development and evaluation of several vaccines at Nabi and Univax Biologics. He is also member of the Scientific Advisory Board of GlycoNet.</p>	
<p><b>Mr. Jorg Thommes</b></p> 	<p>Drug supply leader, Bill &amp; Melinda Gates Medical Research Institute</p>	<p>Mr. Thommes's team is focused on translating the science into physical drugs, vaccines, and monoclonal antibodies. Previously, he was SVP at Visterra Inc. and Biogen. He received a Diplom-Chemiker degree and a Doctorate of Natural Sciences from the University of Bonn and a Habilitation Degree in Biochemical Engineering from the University of Dusseldorf.</p>	
<p><b>Mr. Robin Shattock</b></p> 	<p>Head of Mucosal Infection and Immunity, Department of Medicine, Imperial College London</p>	<p>Robin Shattock's research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. He oversees a portfolio of research that is supported by 26 members of staff and has published over 160 peer reviewed articles in this area.</p>	
<p><b>Mr. Dat Tuan Do</b></p> 	<p>General Director, Vabiotech</p>	<p>Do Tuan Dat is General Director of Vabiotech. He manages all the business, R&amp;D activities and expansion of vaccine supply in Vietnamese market and global markets. Before that, he studied Tropical and Infectious Diseases in Vietnam. He holds a Ph.D in Virology from National Institute of Hygiene and Epidemiology, Vietnam.</p>	

<p><b>Mr. Atin Tomar</b></p> 	<p>President, CPL Biologicals Pvt. Ltd.</p>	<p>Atin Tomar is President at CPL Biologicals. Atin brings with him comprehensive experience in the Biotechnology industry in the areas of Vaccines and Biologics, globally. Atin's expertise spans from Process Development, Scale-up, Technology Transfer and Manufacturing Operations to Business Development, Licensing, Alliance Management and Commercialization.</p>
<p><b>Mr. Rajinder Kumar Suri</b></p> 	<p>Senior Advisor, Panacea Biotech</p>	<p>Rajinder has 38 years of experience in Pharmaceuticals &amp; Biological products in India and International markets and experience at the top management including the Board of Directors of the Indian subsidiary of Sanofi Pasteur. RK Suri is engaged as Senior Advisor with Panacea Biotec and founder CEO &amp; Senior Advisor, Arete Business Advisors, an independent Management &amp; Business Consulting Firm.</p>
<p><b>Mr. Shaozhong Dong</b></p> 	<p>Vice Director, Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS)</p>	<p>Mr. Dong graduated from Kunming Medical College in 1990, and received his PhD of science in Peking Union Medical College in 2003. Be trained as a postdoctoral fellow at Emory University in USA. As the principal investigator, he has been responsible for the researches of Recombinant Human Vaccine of Hepatitis E, New Adjuvant Hepatitis B Vaccine and Rabies Vaccine.</p>
<p><b>Day 2, 30<sup>th</sup> October 2018</b></p>	<p>15:00 - 16:00</p>	<p>Innovative Procurement and Globalization for vaccines Panel Discussion</p>
<p><b>Moderator:</b> <b>Mr. Ed Baker</b></p> 	<p>Market Shaping, GAVI, the Vaccines Alliance</p>	<p>Ed has been working for GAVI for more than 5 years. He is now Senior Specialist, Market Shaping. He previously worked for Merck Serono as Associate Director, Global Market Access &amp; Pricing and at IMS Consulting Group as Strategy Consultant. He holds a Master in Management, Finance, Economics, Marketing and a Bachelor in Molecular Biology from Bath University.</p>

<p><b>Ms. Tania Cernuschi</b></p> 	<p>Team Leader, Vaccine Supply, Technologies &amp; Financing, WHO</p>	<p>Tania Cernuschi leads WHO work on vaccine supply, technologies and financing. WHO IVB work on access to vaccine supply. She 15 years' experience in design and management of development programmes enhancing access to health technologies in resource-constrained settings with Gavi, UNDESA, the Italian Government, UNICEF and NGOs. Tania is a development economist and public health specialist by training.</p>
<p><b>Mr. Dominic Hein</b></p> 	<p>Head, Market Shaping, GAVI, the Vaccine Alliance</p>	<p>Mr. Hein is Head of Market Shaping at Gavi. Previously, he spent 12 years in various parts of GSK's vaccine business, most recently as Executive Director, Global Commercialization and Strategy for the DTP/Hib/Polio Vaccines portfolio. He also has experience in medical practice and management consulting, and holds an MBA from INSEAD, Bsc and MD from University of Birmingham.</p>
<p><b>Mr. John Fitzsimmons</b></p> 	<p>Chief of the Revolving Fund Special Program for Vaccine Procurement, PAHO</p>	<p>John has focused the majority of his career in vaccine preventable diseases at WHO's regional offices and at CDC; working to insure the uninterrupted supply of affordable vaccines in support of regional goals for polio eradication, measles and rubella elimination and the introduction of new vaccines. He received a Master's degree in Urban and Regional Planning from the University of Pittsburgh.</p>
<p><b>Mrs. Ann Egede Ottosen</b></p> 	<p>Contracts Manager, UNICEF Supply Division</p>	<p>Mrs. Ottosen oversees the Global tendering, procurement and contracting of novel vaccines, close collaboration with WHO and GAVI at UNICEF SD. Previously, she was Director, Sales &amp; Marketing, Vaccines at Statens Serum Institut. She holds a Master in business, Language and Culture from Copenhagen Business School.</p>

<p><b>Mrs. Robyn Iqbal</b></p> 	<p>Senior Program Officer, Vaccine Delivery team, Bill &amp; Melinda Gates Foundation (BMGF)</p>	<p>Robyn Iqbal is focused on market dynamics to improve affordable and sustainable supply of vaccines and cold chain equipment to Gavi and support healthy markets. Previously, she worked at Janssen in numerous vaccine and biologic marketing roles and at Merck in vaccine R&amp;D. She holds MBAs from NYU and HEC-Paris, and a MS in Biotechnology from the University of Pennsylvania.</p>
<p><b>Day 2, 30<sup>th</sup> October 2018</b>      16:30 - 17:30      Funding Landscape: New prospects for investing Vaccines Panel Discussion</p>		
<p><b>Moderator:</b> <b>Mr. Glenn Rockman</b></p> 	<p>Partner, GHIF</p>	<p>Mr. Rockman started his career at J.P. Morgan, where he spent more than 10 years working with non-profit organizations, including 3 years with the firm's impact investing unit. He led J.P. Morgan's work with the Gates Foundation to launch the Global Health Investment Fund, where he is currently a Partner.</p>
<p><b>Mr. Frederik Kristensen</b></p> 	<p>Deputy CEO, CEPI</p>	<p>Before CEPI Frederik was a senior advisor on innovation at WHO Geneva, in the Family, Women's and Children's Health Cluster. Previous experience is from the Norwegian Development Agency, health economics, hospital management and the pharmaceutical industry. At the start of his career he worked as a general practitioner in rural settings. He is an MD with a MPH/MBA degree from UC Berkeley.</p>

<p><b>Ms. Mahima Datla</b></p> 	<p>Managing Director, Biological E</p>	<p>Mahima Datla oversees strategic operations and leads the work related to public policy at BE. Mahima is the President of DCVMN's Executive Committee and is currently a member of FICCI and CII National Biotech committees. She is a GHIT fund board member and also an alternate board member with GAVI.</p>
<p><b>Mr. Sai D. Prasad</b></p> 	<p>Product development and commercialization of vaccines and biologics, Bharat</p>	<p>Sai Prasad oversees all aspects of quality management. Previously, he handled operational and strategic activities. He holds a degree in biochemistry from the University of Wisconsin and a MBA in Finance and Marketing from the University of Iowa. Previously he was the Director of Molecular Otolaryngology Research Laboratories at the University of Iowa.</p>
<p><b>Ms. Jenny Yip</b></p> 	<p>Partner, Strategic Investment Fund, Bill &amp; Melinda Gates Foundation (BMGF)</p>	<p>Jenny Yip is a Partner and leads the foundation's strategic investments in China and has completed investments across multiple sectors, ranging from biotech to education technology companies. She also represents the foundation on numerous boards. Prior to joining the Foundation, Jenny was a Vice President and Business Unit Manager at Goldman Sachs in the Investment Banking Division.</p>

**DAY 3, 31<sup>st</sup> October 2018**

<p><b>Day 3, 31<sup>st</sup> October 2018</b></p>	<p>9:00 - 10:30</p>	<p>Regulatory Forum: increasing regulatory convergence</p>
<p><b>Chair:</b> <b>Mrs. Nora Dellepiane</b></p> 	<p>Independent Consultant</p>	<p>With 40 years of experience in production and control of Biological Products, she spent the past twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses on assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals and provides training.</p>
<p><b>Co-Chair:</b> <b>Mr. Samir Desai</b></p> 	<p>President &amp; Head Biologics, Zydus Cadila Healthcare Ltd.</p>	<p>Samir has industry experience of more than three decades having handled sales, training, brand management, marketing and commercial operations. His current role includes commercial operations for vaccines &amp; biologics and small molecules across specialties &amp; geographies, Business Development, In &amp; Out licensing, portfolio planning &amp; liaising with external stakeholders at Zydus Cadila.</p>
<p><b>Ms. Emer Cooke</b></p> 	<p>Head of Regulation of Medicines and Other Health Technologies, WHO</p>	<p>Ms. Cooke was appointed to her current role in 2016. She is from Ireland, a pharmacist with master's degrees in science and Business Administration. With over 30 years' experience in international regulatory affairs, she spent 14 years in management positions at the European Medicines Agency as head of Inspections and head of International affairs.</p>
<p><b>CFDA representative</b></p>		

<p><b>Mr. Diadié Maïga</b></p> 	<p>Regional Vaccine Regulation Officer, WHO Regional Office for Africa</p>	<p>Diadié has served as a Pharmaceutical Systems Officer and Deputy General Director at the Ministry of Health in Mali. Under the umbrella of USAID, Diadié served as the Pharmaceutical Policy Advisor at the Haitian Ministry of Health. He holds a degree in pharmacy from the Faculty of Medicine and Pharmacy of Mali and a PhD in public health from the University of Montreal.</p>
<p><b>Mrs. Nora Dellepiane</b></p> 	<p>Independent Consultant</p>	<p>With 40 years of experience in production and control of Biological Products, she spent the past twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses on assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals and provides training.</p>
<p><b>Mrs. Houda Langar (video)</b></p> 	<p>Regional adviser for regulation and production of vaccines in EMRO, WHO</p>	<p>Houda Langar, Associate professor of Microbiology, is regional adviser for regulation and production of vaccines in EMRO /WHO. She was Desk Officer for UAE from 2014-2017, acting WHO Representative in Djibouti between 2014-2015 and head of Tunisian NCL of vaccines and other biologicals from 1998-2005 prior to join WHO.</p>
<p><b>Day 3, 31<sup>st</sup> October 2018</b>      9:00 - 10:30      Future vaccines Forum</p>		
<p><b>Chair:</b> <b>Mr. Suresh Jadhav</b></p> 	<p>Executive Director, Serum Institute of India</p>	<p>Mr. Jadhav is the Executive Director of Serum Institute of India and was DCVMN's President from 2003 to 2008. He was member on GAVI Board &amp; PPC. He is currently member on European Vaccine Initiative, FastVac and HIP. He is active in several collaborative studies and has published more than 95 technical papers in national &amp; international journals.</p>

<p><b>Co-chair:</b> <b>Mrs. Sumana Khomvilai</b></p> 	<p>Deputy Director, Queen Saovabha Memorial Institute, Thai Red Cross Society</p>	<p>Sumana Khomvilai is a pharmacist with the experience in Pharmaceuticals, Biologicals and Cosmetics Production and Quality Control Technologies and Management for more than 40 years. In addition to her current role, she is also the Advisory Members in many Pharmaceutical and Biological Technology and Research Committee in Thailand.</p>
<p><b>Mr. Jorg Thommes</b></p> 	<p>Drug supply leader, Bill &amp; Melinda Gates Medical Research Institute</p>	<p>Mr. Thommes's team is focused on translating the science into physical drugs, vaccines, and monoclonal antibodies. Previously, he was SVP at Visterra Inc. and Biogen. He received a Diplom-Chemiker degree and a Doctorate of Natural Sciences from the University of Bonn and a Habilitation Degree in Biochemical Engineering from the University of Dusseldorf.</p>
<p><b>Mr. Rajinder Kumar Suri</b></p> 	<p>Senior Advisor, Panacea Biotech</p>	<p>Rajinder has 38 years of experience in Pharmaceuticals &amp; Biological products in India and International markets and experience at the top management including the Board of Directors of the Indian subsidiary of Sanofi Pasteur. RK Suri is engaged as Senior Advisor with Panacea Biotec and founder CEO &amp; Senior Advisor, Arete Business Advisors, an independent Management &amp; Business Consulting Firm.</p>

<p><b>Mr. Rajeev Dhere</b></p> 	<p>Executive Director, Serum Institute of India Limited</p>	<p>Rajeev Dhere, presently an Executive Director at Serum Institute, has a Master's Degree in Microbiology, a Ph.D. in Biotechnology and 41 years of Industrial experience. He moved to Serum Institute in 1987. Since then, he has headed the teams working on Influenza, Rotavirus, Rabies vaccines that have been licensed. He currently heads the R&amp;D groups for Meningococcal, Pneumococcal and Dengue vaccines.</p>
<p><b>Mr. Andrew Wong</b></p> 	<p>Vice President of Business Development, Shanghai Zerun Biotech/Walvax</p>	<p>Mr. Wong is responsible for corporate strategy and business development for a Walvax subsidiary and is managing collaboration with international organizations for Walvax. He received medical, graduate and management trainings in China, Canada and USA. Mr. Wong had 11.5 years' tenure at Amgen by focusing on antibody therapeutics and anticancer drug development.</p>
<p><b>Mr. Lin Du</b></p> 	<p>Executive Director, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</p>	<p>Mr. Lin Du is Executive Director at Zhifei Lvzhu, Inc. He is on the Board of Directors at Chongqing Zhifei Biological Products Co., Ltd. Mr. Du received his graduate degree from Lanzhou University and worked in Lanzhou Institute of Biological Product for 17 years on bacteria vaccine research, then he worked in Zhifei for 10 years on Shigella vaccine.</p>
<p><b>Mrs. Yanchun Che</b></p> 	<p>Head of R&amp;D Department, Medical Biology Chinese Academy of Medical Sciences (IMBCAMS)</p>	<p>Mrs. Yanchun Che is responsible for management of research projects and international collaborative projects by working with WHO, GATES foundation, CMB etc. In recent years, she has been involving in regulatory registration and clinical trials of new vaccines.</p>

Day 3, 31 <sup>st</sup> October 2018 11:00 - 12:30		
Future QC assays and standards Forum: QC Tech transfer to DCVMs		
<p><b>Chair: Mr. Ian Feavers</b></p>	<p>Head of Bacteriology, (NIBSC)</p>	<p>Ian got his PhD at the University of Newcastle upon Tyne, then moved to NIBSC after periods of postdoctoral at the University of Sheffield and the Friedrich Miescher Institute in Basel. Ian is one of NIBSC's observers on Joint Vaccination and Immunisation Committee and a member of the JCVI subgroups. He regularly contributes to WHO and EU guidelines.</p>
<p><b>Co-chair: Ms. Helen Kim</b></p> 	<p>Team Leader, Vaccine Development &amp; Regulatory Affairs, LG Chem, Ltd</p>	<p>Ms. Hyung-Shin (Helen) Kim is a specialist in Development and Regulatory Affairs of vaccines. She is Team Leader of Vaccine Development and Regulatory Affairs in Life Science R&amp;D of LG Chem and has 18 years of professional experience in development, clinical trials and regulatory affairs of biopharmaceutical products, especially vaccines.</p>
<p><b>Mrs. Ute Roskopf</b></p> 	<p>Leader, vaccines testing, World Health Organization (WHO)</p>	<p>Ute is responsible for the qualification of laboratories and skilled in the inspection of manufacturing sites. She gained experience in vaccine production and control of human and veterinary products at the Paul-Ehrlich-Institut. From 2004 she was deputy head of section and head of the laboratory. She is a biologist and holds a doctorate in veterinary biology from the Justus Liebig University of Giessen.</p>
<p><b>Mr. Ian Feavers</b></p>	<p>Head of Bacteriology, (NIBSC)</p>	<p>Ian got his PhD at the University of Newcastle upon Tyne, then moved to NIBSC after periods of postdoctoral at the University of Sheffield and the Friedrich Miescher Institute in Basel. Ian is one of NIBSC's observers on Joint Vaccination and Immunisation Committee and a member of the JCVI subgroups. He regularly contributes to WHO and EU guidelines.</p>

# Annual General Meeting 2018 Speakers Book

<p><b>Mr. David Boyle</b></p> 	<p>Scientific Director,          Diagnostics Program,          PATH</p>	<p>Mr. Boyle is an experienced project leader with a history of working in the clinical microbiology and diagnostic device industry with a specific focus on global health. Skilled in Project Management, Molecular Biology, Clinical Research, Life Sciences, Product Development, Infectious Diseases, and Medical Diagnostics. Strong product development professional with a Ph.D focused in Bacterial Genetics from The University of Edinburgh.</p>
<p><b>Mrs. Neha Agarwal</b></p> 	<p>Commercialization          Officer, Diagnostics          Team, PATH</p>	<p>Neha is responsible for commercialization of a portfolio of diagnostics across a multitude of projects. Previously, she worked at CHAI and for a global health consulting firm. She also worked in the medtech industry, at Johnson &amp; Johnson and Verinata Health. She holds a MS in biomedical engineering from Columbia University and a BS in bioengineering from University of California.</p>
<p><b>Mr. Gideon F A Kersten</b></p> 	<p>Chief Scientific          Officer, InTraVacc</p>	<p>Gideon Kersten is a vaccinologist and department head at the Institute for Translational Vaccinology, InTraVacc, in Bilthoven, The Netherlands. He is responsible for the analytical development and vaccine formulation development at InTraVacc. He has a master in Biochemistry (University of Leiden) and holds a PhD in Pharmacy on subunit vaccines (University of Utrecht).</p>
<p><b>Mrs. Shanda Boyle</b></p> 	<p>Program Officer, Bill          &amp; Melinda Gates          Foundation's Polio          team</p>	<p>Shanda Boyle is a Program Officer at the Bill &amp; Melinda Gates Foundation's Polio team where she focuses her efforts on research and polio vaccine product development to support eradication. Prior to joining the polio team, Shanda worked as part of a large HIV vaccine discovery program. Shanda holds an MPH in global health and an MSc in molecular biology.</p>

<p><b>Mr. Kutub Mahmood</b></p> 	<p>Project Director of the Polio Vaccine Development Projects &amp; Technical Advisor, PATH</p>	<p>Kutub Mahmood focuses primarily on conducting technical assistance for vaccine manufacturers and providing support to help achieve WHO pre-qualification for global supplies of vaccine products. He has been with PATH for over 6 years after 20 years leading viral vaccines discovery and product development efforts in private industry, with stints including at Medimmune, Novavax, Merck, and Vivaldi Biosciences.</p>
<p><b>Day 3, 31 October 2018</b>      11:00 - 12:30      Future vaccines Forum – part 2</p>		
<p><b>Chair:</b> <b>Mr. Andrew Wong</b></p> 	<p>Vice President Business Development, Shanghai Zerun Biotech Walvax</p>	<p>Mr. Wong is responsible for corporate strategy and business development for a Walvax subsidiary and is managing collaboration with international organizations for Walvax. He received medical, graduate and management trainings in China, Canada and USA. Mr. Wong had 11.5 years' tenure at Amgen by focusing on antibody therapeutics and anticancer drug development.</p>
<p><b>Co-chair:</b> <b>Mr. Robin Shattock</b></p> 	<p>Head of Mucosal Infection and Immunity, Department of Medicine, Imperial College London</p>	<p>Robin Shattock's research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. He oversees a portfolio of research that is supported by 26 members of staff and has published over 160 peer reviewed articles in this area.</p>

<p><b>Mr. Carl Kirkwood</b></p> 	<p>Senior Program Officer, Bill and Melinda Gates Foundation</p>	<p>Carl PhD leads the rotavirus initiative tasked with facilitating and supporting the development and introduction of rotavirus vaccines and improving scientific knowledge for preventative and diagnostic aspects of rotavirus disease. Before, Carl was a group leader at Murdoch Children's Research Institute (Australia), and director of a WHO Collaborating Centre (rotavirus research) and WHO Regional Rotavirus Reference Laboratory.</p>
<p><b>Mr. Sanjeev Kumar</b></p> 	<p>President, Zydus Cadila</p>	<p>Sanjeev Kumar has been Zydus Cadila's president for more than 15 years. He holds a Postdoc in Immunology from Vanderbilt University, a Ph.D in Immunology - Antigen processing and presentation from the National Institute of Immunology and a M.Sc. In Biotechnology from Madurai Kamaraj University.</p>
<p><b>Mr. Sotiris Missailidis</b></p> 	<p>Deputy Director, Bio-Manguinhos Technological Development</p>	<p>Prior to his current role, Mr. Missailidis has acted as a biotechnologist at the Laboratory of Monoclonal Antibodies Technology. He was a senior researcher at the Osvaldo Cruz Institute Hantavirus and Rickettsiosis Laboratory. He holds a Phd in Pharmaceutical Sciences and Molecular Biology from the Universities of Nottingham and Cambridge. Doctor and Master of Chemistry from York University.</p>
<p><b>Mr. Weining Meng</b></p> 	<p>Director of International Regulatory Affairs and Business, Sinovac Biotech</p>	<p>Mr. Weining Meng has joined Sinovac in 2007. He has worked as international regulatory manager, QA manager and international regulatory director in Sinovac in the past 10 years. During this period, he has led the team to make Sinovac's first vaccine passed WHO prequalification in 2017. Currently, he is in charge of international business and international regulatory affairs in Sinovac.</p>

<p><b>Mr. James Wai Kuo Shih</b></p> 	<p>Senior Advisor, Xiamen Innovax Biotech Co.</p>	<p>Mr. James Wai Kuo Shih has been a consultant for Xiamen Innovax for more than 12 years. He also serves as a biomedical scientist at Xiamen University. Previously, he worked as Senior Principle Investigator at the National Institutes of Health. He holds a Doctor of Philosophy (Ph.D.), Microbiology and Immunology from Vanderbilt University.</p>
<p><b>Mr. Alexander Precioso</b></p> 	<p>Clinical Director, Instituto Butantan</p>	<p>Alexander R Precioso is Clinical Director of Instituto Butantan, São Paulo with expertise in Clinical Trials, Epidemiology, Pediatrics and vaccine research. He has been responsible for coordinating the integration between the Project Management Office, the Technology Transfer Office, and The Innovation Technology Unit at Butantan institute since 2015.</p>
<p><b>Day 3, 31<sup>st</sup> October 2018</b>    14:00 - 15:30    Novel strategies to improve vaccine coverage and equity</p>		
<p><b>Chair:</b> <b>Mrs. Birgitte Giersing</b></p> 	<p>Technical officer, Department of Immunizations, Vaccines and Biologics, WHO</p>	<p>Mrs. Giersing performed her post-doctoral studies at the NIH in malaria vaccines. She then joined PATH, to oversee development of early stage malaria vaccine candidates. In 2007, she moved into private industry. She joined the WHO in 2014 and is the secretariat for the Product Development Vaccine Advisory Committee and the co-chair of WHO's Delivery Technologies Working Group.</p>
<p><b>Co-Chair:</b> <b>Mr. Steven Gao</b></p> 	<p>General Manager, Xiamen INNOVAX Biotech Co., Ltd.</p>	<p>Before joining Innovax, Mr. Gao worked as a Director and a Vice President for sales and marketing in the biopharma industry. During his ten years, Mr. Gao held various key positions in quality control and sales and marketing and was eventually promoted to President of the company.</p>

<p><b>Mrs. Birgitte Giersing</b></p> 	<p>Technical officer,        Department of        Immunizations,        Vaccines and        Biologics, WHO</p>	<p>Mrs. Giersing performed her post-doctoral studies at the NIH in malaria vaccines. She then joined PATH, to oversee development of early stage malaria vaccine candidates. In 2007, she moved into private industry. She joined the WHO in 2014 and is the secretariat for the Product Development Vaccine Advisory Committee and the co-chair of WHO's Delivery Technologies Working Group.</p>
<p><b>Moderator:</b>  <b>Ms. Debra Kristensen</b></p> 	<p>Director, Vaccine and        Pharmaceutical        Technologies,        PATH</p>	<p>Debra Kristensen oversees PATH's work in vaccine and pharmaceutical formulation, delivery and packaging, and supply systems and equipment. She is responsible for portfolios of projects centered on advancing product and system innovations that reduce costs, ease logistics, improve safety, expand coverage, and maximize public health impact in low-resource settings.</p>
<p><b>Mrs. Ritika Kapoor</b></p> 	<p>Health Technology        Assessment Expert,        National University of        Singapore</p>	<p>Ritika Kapoor's areas of expertise are economic modelling for Cost-effectiveness analysis, Economic Burden Evaluations and Budget Impact Analysis. She holds an Integrated Dual Degree Course (B.tech &amp; M.Tech) Biochemical Engineering from the Indian Institute of Technology (Banaras Hindu University), Varanasi.</p>
<p><b>Mr. Carl Kirkwood</b></p> 	<p>Senior Program        Officer, Bill and        Melinda Gates        Foundation</p>	<p>Carl PhD leads the rotavirus initiative tasked with facilitating and supporting the development and introduction of rotavirus vaccines and improving scientific knowledge for preventative and diagnostic aspects of rotavirus disease. Before, Carl was a group leader at Murdoch Children's Research Institute (Australia), and director of a WHO Collaborating Centre (rotavirus research) and WHO Regional Rotavirus Reference Laboratory.</p>

<p><b>Mr. Dominic Hein</b></p> 	<p>Head, Market Shaping, GAVI, the Vaccine Alliance</p>	<p>Mr. Hein is Head of Market Shaping at Gavi. Previously, he spent 12 years in various parts of GSK's vaccine business, most recently as Executive Director, Global Commercialization and Strategy for the DTP/Hib/Polio Vaccines portfolio. He also has experience in medical practice and management consulting, and holds an MBA from INSEAD, Bsc and MD from University of Birmingham.</p>
<p><b>Mr. Yeong-Ok Baik</b></p> 	<p>CEO, EuBiologics</p>	<p>Mr. Yeongok Baik has more than 30 years of experience in biotechnology industry starting his career at CJ Corporation. He founded EuBiologics Co., Ltd in 2010 and is currently the CEO. He graduated from Seoul National University in Veterinary Medicine and has a Ph.D in Life Science from Korea University.</p>
<p><b>Mr. Suresh Jadhav</b></p> 	<p>Executive Director, Serum Institute of India</p>	<p>Mr. Jadhav is the Executive Director of Serum Institute of India and was DCVMN's President from 2003 to 2008. He was member on GAVI Board &amp; PPC. He is currently member on European Vaccine Initiative, FastVac and HIP. He is active in several collaborative studies and has published more than 95 technical papers in national &amp; international journals.</p>
<p><b>Day 3, 31<sup>st</sup> October 2018</b>    14:00 - 15:30    Updates on progress of UNICEF</p>		
<p><b>Chair: Ms. Etleva Kadilli</b></p> 	<p>Director, UNICEF's Supply Division</p>	<p>Etleva Kadilli is responsible for the provision of supplies through direct UNICEF programmes, cooperation with Governments and partners. Prior, Ms. Kadilli was Deputy Director, Supply Chain, in charge of the management of UNICEF's supply response to humanitarian crises, contracting policy and procedures, quality assurance of UNICEF-procured products, global logistics operations and the professional development of UNICEF's supply and logistics staff.</p>

<p><b>Co-Chair:</b> <b>Mrs. Yalda Momeni</b></p> 	<p>Contracts Manager for EPI Routine Vaccines, UNICEF</p>	<p>Mrs. Yalda Momeni has been working for UNICEF for more than 14 years. Prior to her current position, she was the Program Supply Chain Specialist - Health &amp; Nutrition at UNICEF in Mozambique and Contracts Specialist - Vaccine Analyst at UNICEF Denmark.</p>
<p><b>Moderator:</b> <b>Ms. Etleva Kadilli</b></p> 	<p>Director, UNICEF's Supply Division</p>	<p>Etleva Kadilli is responsible for the provision of supplies through direct UNICEF programmes, cooperation with Governments and partners. Prior, Ms. Kadilli was Deputy Director, Supply Chain, in charge of the management of UNICEF's supply response to humanitarian crises, contracting policy and procedures, quality assurance of UNICEF-procured products, global logistics operations and the professional development of UNICEF's supply and logistics staff.</p>
<p><b>Mrs. Yalda Momeni</b></p> 	<p>Contracts Manager for EPI Routine Vaccines, UNICEF</p>	<p>Mrs. Yalda Momeni has been working for UNICEF for more than 14 years. Prior to her current position, she was the Program Supply Chain Specialist - Health &amp; Nutrition at UNICEF in Mozambique and Contracts Specialist - Vaccine Analyst at UNICEF Denmark.</p>
<p><b>Ms. Tania Cernuschi</b></p> 	<p>Team Leader, Vaccine Supply, Technologies &amp; Financing, WHO</p>	<p>Tania Cernuschi leads WHO work on vaccine supply, technologies and financing. WHO IVB work on access to vaccine supply. She 15 years' experience in design and management of development programmes enhancing access to health technologies in resource-constrained settings with Gavi, UNDESA, the Italian Government, UNICEF and NGOs. Tania is a development economist and public health specialist by training.</p>

<p><b>Mrs. Robyn Iqbal</b></p> 	<p>Senior Program Officer, Vaccine Delivery team, Bill &amp; Melinda Gates Foundation (BMGF)</p>	<p>Robyn Iqbal is focused on market dynamics to improve affordable and sustainable supply of vaccines and cold chain equipment to Gavi and support healthy markets. Previously, she worked at Janssen in numerous vaccine and biologic marketing roles and at Merck in vaccine R&amp;D. She holds MBAs from NYU and HEC-Paris, and a MS in Biotechnology from the University of Pennsylvania.</p>
<p><b>Mrs. Nine Steensma</b></p> 	<p>Director, Vaccines Markets, CHAI</p>	<p>Nine Steensma has gained cross-sector experience working at McKinsey and Company as well as MSF. She has been with CHAI since 2010 focusing primarily on the Essential Medicines Team and now the Global Vaccines Markets Team. She holds a LL.M in International Law and MSc in International Business.</p>
<p><b>Mr. Rajinder Kumar Suri</b></p> 	<p>Senior Advisor, Panacea Biotech</p>	<p>Rajinder has 38 years of experience in Pharmaceuticals &amp; Biological products in India and International markets and experience at the top management including the Board of Directors of the Indian subsidiary of Sanofi Pasteur. RK Suri is engaged as Senior Advisor with Panacea Biotech and founder CEO &amp; Senior Advisor, Arete Business Advisors, an independent Management &amp; Business Consulting Firm.</p>
<p><b>Mr. Shi Li</b></p> 	<p>Vice President, Walvax Biotechnology Co., Ltd. &amp; CEO, Shanghai Zerun Biotechnology Co., Ltd.</p>	<p>Mr. Shi graduated from Beijing University and the University of California. Dr. Shi joined Merck after his postdoctoral work in San Diego. At Merck, Dr. Shi was involved in multiple vaccines and other biopharmaceutical product research and development. Prior to joining Zerun Bio, Dr. Shi worked in Genzyme as Senior Director of Technology.</p>

# Annual General Meeting 2018 Speakers Book

Day 3, 31 <sup>st</sup> October 2018		
16:00 - 17:00		Plenary Closing Session
<p><b>Chair:</b> <b>Mr. Alexander Precioso</b></p> 	<p>Clinical Director, Instituto Butantan</p>	<p>Alexander R Precioso is Clinical Director of Instituto Butantan, São Paulo with expertise in Clinical Trials, Epidemiology, Pediatrics and vaccine research. He has been responsible for coordinating the integration between the Project Management Office, the Technology Transfer Office, and The Innovation Technology Unit at Butantan institute since 2015.</p>
<p><b>Closing Keynote Lecture:</b> <b>Mrs. Claudia Nannei</b></p> 	<p>Health economist, WHO</p>	<p>Mrs. Nannei is a health economist. She has worked for more than 12 years in university hospitals. She joined WHO in 2009 to lead the work on performance, monitoring and evaluation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. She holds a MA. in Management of Public Health Institution from the Università di Pisa.</p>
<p><b>Closing Remarks</b></p>	<p>Host of AGM 2019</p>	